Corteria Pharmaceuticals

About Corteria Pharmaceuticals

Corteria Pharmaceuticals, founded in 2021, is a privately held company focused on developing first-in-class drugs for high unmet medical needs in heart failure, sarcopenia, and obesity subpopulations. Their strategy involves innovative patient stratification and target selection based on human evidence and a deep understanding of disease biology, aiming to create transformative therapies for worsening and acute decompensated heart failure.

Products & Services

COR-1167:A first-in-class CRF2 agonist entering Phase 2 clinical trials for the treatment of Worsening Heart Failure, with promising Phase 1 data.

COR-2007:A drug candidate in the portfolio, specifics not detailed in the content.

CRF2 Peptide Agonist Project:A project focused on developing therapies using CRF2 peptide agonists for heart failure treatment.

Specialties

Heart Failure Treatment Sarcopenia Treatment Obesity Treatment Patient Stratification CRF2 Agonists Vasopressin Neutralizing Antibodies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 71000000 MR: - FA: EUR 65 million FAN: 71000000	D: 2023-09-07 FD: 2023-09-07	7 investors

Series A Latest

2023-09-07

$71.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alexandre Mebazaa

Professor

A

Adriaan Voors

Professor

J

Jeffrey Testani

MD

W

Williams Evans

PhD

P

Philip Janiak

CEO

M

Mark Pruzanski

Chairman

View 16 more team members with Pro

Unlock Full Team Directory

Recent News